Drug intelligence / Profile preview

B-106

Development stage: Preclinical
Lead developer: Biologx
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

**B-106** is a preclinical BiologX premixed 70/30 biosimilar insulin candidate intended for glycemic control in type 1 diabetes and type 2 diabetes. The archived BiologX pipeline described it generically as a combination insulin biosimilar that activates the insulin receptor; no nonproprietary name, marketed brand, precise insulin components, or reference biologic was publicly specified for this exact asset. ([web.archive.org](https://web.archive.org/web/20220816102009/https%3A//www.biologx.com/pipeline))

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on B-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-106.

Explore the full profile